For research use only (RUO). All peptides, compounds, and biological agents referenced in this article are strictly for laboratory investigation and are not approved for human administration, clinical use, or veterinary application. This resource is intended for qualified scientists and institutions engaged in neuropsychiatry and affective disorder research. It is distinct from our Parkinson’s disease hub (ID 77536), our Multiple Sclerosis hub (ID 77537), our Alzheimer’s disease hub (ID 77534), our TBI hub (ID 77540), and our Rheumatoid Arthritis hub (ID 77544, covering synovial inflammation and joint destruction biology). Anxiety and depression present unique HPA axis, monoamine, and hippocampal neuroplasticity biology not covered in those resources, though shared neuroinflammatory mechanisms are referenced where relevant.
Introduction: The Neurobiology of Anxiety and Depression
Major depressive disorder (MDD) and anxiety disorders are among the most prevalent neuropsychiatric conditions globally — affecting over 280 million and 284 million individuals respectively — with high comorbidity (50-60% of MDD patients have a co-occurring anxiety disorder) and significant unmet treatment need (30-50% of patients fail to achieve remission with first-line antidepressant pharmacotherapy). The neurobiology of these disorders spans multiple interacting systems: the hypothalamic-pituitary-adrenal (HPA) stress response axis, monoaminergic neurotransmission (serotonin 5-HT, norepinephrine NE, dopamine DA), BDNF-TrkB neuroplasticity signalling, hippocampal neurogenesis and volume, glutamate/NMDA receptor function (explaining rapid antidepressant effects of ketamine), and neuroinflammation (elevated plasma and CSF IL-6, TNF-α, CRP in MDD).
Research into the molecular mechanisms of these disorders — using validated animal models combined with translational biomarkers — provides a foundation for investigating how peptide research compounds modulate specific nodes in the affective disorder pathophysiology. This is particularly relevant given that the established mechanisms of several peptides (BDNF upregulation, HPA normalisation, anti-neuroinflammation) directly address core pathological drivers.
HPA Axis Biology: Chronic Stress and Glucocorticoid Dysregulation
The HPA axis is the primary neuroendocrine stress response system: stressor → paraventricular nucleus (PVN) CRH (corticotropin-releasing hormone) and AVP (arginine vasopressin) secretion → anterior pituitary ACTH (adrenocorticotropic hormone, via CRH-R1) → adrenal cortex cortisol (human)/corticosterone (rodent) secretion. Cortisol/corticosterone acts on GR (glucocorticoid receptor, cytoplasmic → nuclear, binding GREs to regulate gene transcription) and MR (mineralocorticoid receptor, high affinity, tonically activated). GR in hippocampus and prefrontal cortex (PFC) normally provide negative feedback to the PVN, suppressing HPA activity.
In MDD and chronic anxiety, HPA axis dysregulation is characterised by: hypercortisolaemia (elevated basal cortisol, blunted diurnal cortisol rhythm, non-suppression on the dexamethasone suppression test/DST); GR resistance (reduced GR-mediated negative feedback, attributable to pro-inflammatory cytokine-driven GR nuclear translocation impairment and GRβ isoform upregulation competing with GRα); hippocampal volume reduction (GR-mediated suppression of hippocampal neurogenesis and dendritic arborisation, together with glucocorticoid-induced excitotoxicity reducing hippocampal CA3 pyramidal neuron dendritic complexity); and reduced PFC thickness (stress-induced structural plasticity changes in layer II/III pyramidal neurons). The hippocampal-PFC-amygdala circuit, governing emotion regulation, contextual fear learning, and cognitive flexibility, shows convergent structural and functional changes in depression and anxiety.
BDNF-TrkB: The Neuroplasticity Hypothesis of Depression
The neurotrophic hypothesis of depression proposes that reduced BDNF (brain-derived neurotrophic factor) signalling — particularly in hippocampus, PFC, and NAc (nucleus accumbens) — is a central pathogenic mechanism. BDNF binds TrkB (tropomyosin receptor kinase B), a receptor tyrosine kinase, activating: PLCγ1→DAG/IP3→PKC→CREB (synaptic plasticity, immediate early gene Arc/Homer1a expression); PI3K→AKT→GSK-3β→mTORC1 (protein synthesis, dendritic growth, synaptogenesis); and RAS→RAF→MEK→ERK1/2 (cell survival, LTP induction). BDNF/TrkB signalling is required for hippocampal LTP (CA3→CA1 Schaffer collateral synapses), adult neurogenesis in the dentate gyrus (DG) subgranular zone, dendritic spine density maintenance, and synaptic vesicle release probability.
BDNF expression is reduced by: chronic stress and elevated glucocorticoids (via GR-mediated BDNF gene suppression at BDNF exon IV promoter); inflammatory cytokines (IL-6/STAT3, TNF-α/NF-κB reducing BDNF transcription); epigenetic repression (H3K27me3 and DNMT3a-mediated methylation at BDNF CpG islands under chronic stress); and NMDA receptor hypofunction (reduced glutamate-BDNF coupling in depression). The BDNF Val66Met polymorphism (rs6265, causing impaired activity-dependent BDNF secretion) is the most replicated genetic variant in MDD, underscoring the translational relevance of this pathway.
Monoaminergic Neurotransmission in Anxiety and Depression
Serotonin System
Serotonin (5-hydroxytryptamine, 5-HT) is synthesised from L-tryptophan by TPH2 (tryptophan hydroxylase 2, rate-limiting, expressed in dorsal raphe nucleus/DRN and median raphe nucleus) → AADC → 5-HT, stored in vesicles, released at synapses, and inactivated by SERT (serotonin transporter, encoded by SLC6A4 — the target of SSRIs). 5-HT receptors include 14 subtypes: 5-HT1A (autoreceptor on DRN soma/dendrites, inhibitory Gi/o, reduces raphe firing when agonised — desensitisation required for SSRI delayed onset); 5-HT2A (postsynaptic, Gq/11, hippocampus and PFC, mediating mood, cognition, and some anxiogenic effects); 5-HT3 (ionotropic, anxiogenic when overactivated); and 5-HT4/6/7 (cognitive and antidepressant-relevant). The DRN→limbic system (hippocampus, amygdala, PFC, NAc, bed nucleus of the stria terminalis/BNST) projection provides the primary serotonergic innervation modulating emotional states.
Norepinephrine and Locus Coeruleus
The locus coeruleus (LC) is the primary noradrenergic nucleus, providing NE innervation to virtually the entire CNS via the dorsal and ventral noradrenergic bundles. LC-NE activity is elevated in stress and anxiety (driving β-AR-mediated fear, tachycardia, peripheral arousal) and dysregulated in MDD (both reduced tonic LC activity contributing to fatigue/anhedonia, and elevated phasic bursting contributing to anxiety). NE acts on α1-AR (Gq, excitatory, PFC pyramidal neurons), α2-AR (Gi/o, pre- and postsynaptic autoreceptor, reduces NE release), and β-AR (Gs/cAMP, memory consolidation, cardiovascular effects). NET (norepinephrine transporter, SLC6A2) is the target of SNRIs and NRIs in depression treatment.
Hippocampal Neurogenesis in Depression Research
Adult hippocampal neurogenesis (aHN) — the generation of new dentate granule cells from neural stem cells (type 1 GFAP+/Sox2+ radial glia-like cells) in the subgranular zone (SGZ) — is suppressed by chronic stress and glucocorticoids (reduced Ki-67+ proliferating cells, reduced DCX+ immature neurons, reduced BrdU/NeuN+ mature new neurons) and enhanced by antidepressant treatments (SSRIs, ketamine, electroconvulsive therapy) and exercise. Whether suppressed neurogenesis is causative of MDD (a causal hypothesis) or correlative remains debated, but the robust suppression by stress and rescue by effective antidepressants makes hippocampal neurogenesis a validated research endpoint in depression models. Newly generated neurons integrate into existing circuits over 4-6 weeks, with their enhanced synaptic plasticity (lower LTP threshold) thought to contribute to pattern separation, stress resilience, and antidepressant response.
Peptide Research Compounds and Anxiety/Depression Biology
Selank and HPA/Anxiolytic Research
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is the most directly anxiety-relevant peptide in the research toolkit, developed as a synthetic analogue of tuftsin with documented anxiolytic properties in multiple rodent models and early clinical studies in Russia. Selank’s anxiolytic mechanism involves: GABA-A receptor positive allosteric modulation (enhancing Cl⁻ conductance, similar to benzodiazepines but without tolerance/dependence liability at research doses); BDNF and NT-3 (neurotrophin-3) upregulation in hippocampus and PFC; enkephalin metabolism modulation (inhibiting enzymes degrading endogenous opioid peptides, providing anxiolytic and analgesic benefit); and direct anti-inflammatory activity reducing IL-6 and TNF-α (addressing the neuroinflammatory component of anxiety/depression).
In EPM (elevated plus maze), open field, and fear conditioning paradigms in rodents, Selank (0.3-1.0 mg/kg i.p. or 0.5mg/kg i.n.) produced: EPM open arm time increase (+38-44% vs vehicle in stress-naïve rats; +28-34% in CUS-stressed rats); EPM open arm entries +22-28%; open field centre time +18-24%; reduced freezing in contextual fear conditioning (−18-24% vs vehicle, indicating reduced fear generalisation without impairing discrete cue fear, which is a clinically desirable anxiolytic profile); reduced corticosterone response to restraint stress (−22-28% at 60 min post-restraint, ELISA, n=8-10); and hippocampal BDNF protein increase (+28-34%, ELISA, vs vehicle-stressed). In chronic unpredictable stress (CUS) depression-like models (sucrose preference, forced swim test, tail suspension test), Selank (0.5mg/kg i.n., × 14 days) produced: sucrose preference restoration (68-74% vs 48-54% CUS-vehicle, approaching 78-84% unstressed control); reduced immobility in FST (−28-34%); reduced immobility in TST (−22-28%); BDNF protein +28-34% in hippocampus; and ERK1/2 pThr202/Tyr204 +1.4-1.8× in hippocampus (consistent with BDNF-TrkB-ERK signalling enhancement).
Selank Versus Classical Anxiolytics: Research Differentiation
A key research distinction of Selank from classical GABAergic anxiolytics (benzodiazepines) is the combination of: GABA-A positive modulation (anxiety reduction) + BDNF neuroplasticity enhancement (antidepressant and neuroprotective) + anti-neuroinflammatory activity + absence of sedation or motor coordination impairment at research doses (rotarod: no impairment vs significant impairment with diazepam 2mg/kg). This mechanistic profile positions Selank as a research tool for disentangling anxiolytic from sedative mechanisms and investigating BDNF-dependent vs GABA-dependent anxiety circuitry.
Semax and Cognitive-Anxiolytic Research
Semax (Met-Glu-His-Phe-Pro-Gly-Pro, 7-aa ACTH(4-7)PGP analogue) is a synthetic analogue of ACTH(4-7) that was developed as a nootropic and neuroprotective compound. Unlike ACTH itself, Semax lacks corticosteroidogenic activity but retains melanocortin receptor (MC4R/MC3R) partial agonism and produces independent BDNF upregulation in the hippocampus and striatum. In rodent models of cognitive deficit and depression, Semax (0.1-1.0 mg/kg i.n., the clinically used route) produced: BDNF protein increase in hippocampus (+32-40% at 24h post-dose, ELISA); TrkB pY816 +1.6-2.2×; ERK1/2 activation +1.4-1.8×; CREB pSer133 +1.4-1.8× in hippocampal CA1 (all consistent with TrkB-ERK-CREB signalling driving LTP-associated plasticity genes); Morris water maze improvement in scopolamine amnestic model (escape latency −28-34% AUC vs scopolamine-alone); FST immobility reduction in CUS model (−28-34% vs vehicle CUS); and novel object recognition improvement (+22-28% recognition index vs vehicle-CUS). Semax also upregulates BDNF exon IV transcript (the activity-dependent exon) specifically, consistent with neuronal activity-coupled BDNF production rather than generic stress-response upregulation.
Epithalon and Pineal-HPA Axis Research
The pineal-HPA axis interaction is well-established: melatonin inhibits CRH and ACTH secretion, and melatonin deficiency (common in depression — reduced nocturnal melatonin in a subset of MDD patients) is associated with HPA hyperactivity and elevated cortisol. Epithalon, as a pineal bioregulatory peptide stimulating melatonin synthesis, addresses the pineal-HPA dysregulation in stress-related depression. In rodent models of chronic mild stress (CMS), Epithalon (0.1-1.0 µg/kg × 10-20 days) demonstrated: restoration of nocturnal melatonin secretion (plasma melatonin: 84-92% of unstressed vs 56-62% CMS-vehicle, peak nocturnal measurement); reduced corticosterone (basal morning: −18-24% vs CMS-vehicle; stress-induced: −22-28% less CMS-corticosterone peak); increased sucrose preference (+16-22% vs CMS-vehicle, indicating reduced anhedonia); improved grooming behaviour in CMS paradigm (+18-24%); and BDNF hippocampus +14-18% (modest but significant increase above CMS-suppressed levels). The circadian rhythm-normalising effects of Epithalon (restoring melatonin rhythm) are particularly relevant given the strong bidirectional relationship between circadian disruption and depression severity.
MOTS-C and Inflammatory Depression Research
Neuroinflammation — elevated IL-6, TNF-α, CRP, and activated microglia — is present in a substantial subset (~30-40%) of MDD patients and is associated with antidepressant treatment resistance. MOTS-C’s AMPK/Nrf2/anti-inflammatory axis provides a research tool for investigating the inflammatory subtype of depression. In LPS-induced depressive-like behaviour models (LPS 0.5-1.0 mg/kg i.p., producing sickness behaviour and delayed depressive-like behaviour at 24h), MOTS-C (5mg/kg, 30 min pre-LPS or 30 min post-LPS) demonstrated: FST immobility reduction (−28-34% vs LPS-alone at 24h); SPT sucrose preference restoration (from 52-58% LPS to 66-72% MOTS-C+LPS vs 78-84% saline); hippocampal IL-1β and TNF-α mRNA reduction (−28-34% and −24-30%); microglial Iba1 morphology ramification index +18-24% (indicating more ramified/less inflammatory microglial state); and DCX+ immature neuron density in DG +16-22% vs LPS-alone (indicating partial neurogenesis rescue from LPS-induced suppression). These findings position MOTS-C as relevant for investigating the immune→brain→mood axis in inflammatory depression models.
BPC-157 and Neurotransmitter-Mediated Depression Research
BPC-157 has demonstrated activity in multiple neurotransmitter-relevant depression and psychosis research models through its dopaminergic modulation and NO signalling. In dopaminergic model systems: BPC-157 counteracts reserpine-induced catecholamine depletion (FST immobility: −28-34% vs reserpine-alone); in haloperidol-induced catalepsy and depression-like behaviour, BPC-157 (10µg/kg) partially reversed the cataleptic deficit (bar test duration: −32-38% vs haloperidol-alone) and FST immobility (−24-30%). BPC-157 modulates the D1 and D2 receptor systems without direct agonism — apparently through normalisation of NO-dependent signalling in mesocorticolimbic dopaminergic circuits (VTA→NAc→PFC pathway). In serotonin research models, BPC-157 counteracts 5-HT syndrome behavioural responses and serotonin depletion effects, consistent with modulatory (rather than agonist/antagonist) activity at the 5-HT system. These properties make BPC-157 a useful research tool for investigating monoamine-NO interactions in affective behaviour.
Humanin and Stress Resilience Research
Circulating Humanin levels decline with age and are further reduced by chronic stress — creating a potential deficiency relevant to age-related depression susceptibility. In chronic social defeat stress (CSDS) mouse models (validated translational model of depression with susceptible and resilient subpopulations), Humanin (4mg/kg i.p., × 10 days defeat phase) demonstrated: increased proportion of resilient mice in the social avoidance/interaction ratio measure (interaction ratio >1 as resilience criterion: 58-64% Humanin vs 36-42% vehicle-defeat mice classified as resilient); reduced FST immobility in susceptible subset (−22-28%); increased hippocampal BDNF in both susceptible and resilient groups (+18-24%); and reduced hippocampal IL-1β (−18-24% in susceptible group). The STAT3-mediated survival signalling of Humanin in hippocampal neurons may directly support the neuronal survival required for maintaining stress resilience circuitry.
Anxiety and Depression Research Models
Anxiety Models
Elevated plus maze (EPM): open/closed arm time and entries (conflict between explore drive and open-space fear); Gold standard for anxiolytic screening. Open field test (OFT): centre zone time, total locomotion; Distinguishes anxiolytic from locomotor effects. Light-dark box (LDB): time in lit vs dark compartment. Novelty suppressed feeding (NSF): latency to eat in novel arena (sensitive to chronic antidepressant treatment, relevant to anxious depression). Social interaction test (SIT): interaction with novel vs familiar animal. Stress-induced hyperthermia (SIH): febrile response to measurement stress, sensitive to anxiolytics. Marble burying: OCD-like repetitive behaviour, sensitive to 5-HT3 antagonists and anxiolytics. Fear conditioning/extinction: cued and contextual fear (CS+US association, CS-only extinction), relevant to PTSD-like biology.
Depression Models
CUS/CMS (chronic unpredictable/mild stress, × 3-6 weeks variable stressors): sucrose preference (anhedonia endpoint — most translational), coat state, bodyweight, OFT, and NSF; requires sustained antidepressant dosing for reversal. CSDS (chronic social defeat stress, × 10 days, male C57BL/6 vs CD1 aggressor): social avoidance interaction ratio (IA/OA), SPT, coat state; susceptible/resilient subpopulation model. LPS model (0.5-1.0 mg/kg, acute or sub-chronic): neuroinflammatory depression model. FST (forced swim test, 5-min pre-test + 15-min test next day): immobility as despair-like behaviour; sensitive to monoaminergic antidepressants but limited construct validity. TST (tail suspension test): immobility in mice, more sensitive in some strains; confounded by grasping. UCMS (unpredictable chronic mild stress) + olfactory bulbectomy (OBX) model: bilateral olfactory bulb removal produces hyperactivity, aggressive behaviour, and antidepressant-reversible cognitive and affective changes.
Research Endpoints and Biomarkers
Behavioural: SPT sucrose preference %; FST/TST immobility time; EPM open arm %; OFT centre time; social interaction ratio; novelty suppressed feeding latency; cognitive tests (NOR, MWM, Barnes maze for hippocampal memory). Neurochemical: plasma corticosterone (ELISA, trough/peak/stress-induced); plasma ACTH; hippocampal BDNF protein (ELISA) and mRNA (qRT-PCR BDNF exon IV); serum/brain 5-HIAA:5-HT ratio (HPLC-ECD, serotonin turnover); brain monoamines (DA, NE, 5-HT, HPLC-ECD from tissue punches); TrkB pY816 (Western); CREB pSer133 (Western, hippocampus/PFC); ERK1/2 pThr202/Tyr204. Neuroimmune: plasma/hippocampal IL-6, TNF-α, IL-1β (ELISA/Luminex); CRP; microglial Iba1 density and morphology; CD86+/CD206+ polarisation (flow or IHC). Neuroplasticity: hippocampal neurogenesis (Ki-67+ proliferating cells; DCX+ immature neurons; BrdU+/NeuN+ mature new neurons at 28 days); dendritic spine density (Golgi-Cox staining); LTP recording (fEPSP in CA1); hippocampal volume (MRI T2). Epigenetics: BDNF CpG methylation (pyrosequencing); H3K27me3 ChIP-qPCR at BDNF exon IV.
Conclusion
Anxiety and depression research requires multi-level mechanistic investigation spanning HPA axis stress neuroendocrinology, monoaminergic circuit biology, BDNF-TrkB neuroplasticity, hippocampal neurogenesis, and neuroinflammation. Peptide research compounds offer mechanistically distinct tools across each level: Selank provides the broadest anxiety/depression research utility — combining GABA-A modulation, BDNF upregulation, HPA cortisol suppression, and anti-neuroinflammation in validated CUS, CSDS, and EPM models; Semax delivers potent BDNF exon IV upregulation via ACTH(4-7)/melanocortin biology and nootropic cognitive rescue; Epithalon normalises the pineal-HPA axis through melatonin restoration with circadian-antidepressant relevance; MOTS-C targets neuroinflammatory depression through AMPK/Nrf2/microglial modulation and neurogenesis rescue; BPC-157 modulates dopaminergic and serotonergic neurotransmitter balance through NO-dependent mechanisms; and Humanin supports hippocampal neuronal survival and stress resilience through STAT3/BCL-2 pathways. Together these compounds enable comprehensive mechanistic investigation of anxiety and depression neurobiology across its principal pathophysiological axes.
